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Introduction 
Menthol (2-isopropyl-5-methyl-cyclohexanol), a 
cyclic alcohol widely appreciated for its ability to 
produce a cooling sensation, has been used as a 
constituent of food and drink, tobacco and cos- 
metics. This compound can reduce flatulence and 
colic pain in patients with irritable bowel syndrome 
probably through blockade of Ca2+ channels on 
intestinal smooth muscle (1). A recent report 
indicates that menthol vapour possesses an anti- 
tussive action (2). The objective of the present study 
was to investigate the effect of menthol on airway 
hyperresponsiveness in asthma. 
Patients and Methods 
Twenty-three non-smoking subjects with chronic 
mild asthma (twelve males, eleven females; aged 
1946 years) (3) were enrolled into the trial after 
obtaining written informed consent. None of the 
patients had had either exacerbation of wheezing or 
respiratory infection in the preceding 4 weeks. Each 
subject had only occasional symptoms, which were 
controlled by &adrenoceptor agonists from metered 
dose inhalers on demand. 
The study had a randomized, placebo-controlled 
design, which was approved by Tokyo Women’s Medi- 
cal College Ethics Committee. After a 2-week run-in 
period, subjects were randomized to receive nebulized 
menthol (10 mg, twice a day, Hohei Co., Tokyo, Japan) 
or matching placebo for 4 weeks. This dose of menthol 
was chosen based on the report by Laude et al. (2). Each 
subject was given a mini-Wright peak flow meter to 
record peak expiratory flow rate (PEFR) twice a day (at 
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awakening and on going to bed) before inhalation of 
menthol, placebo or &agonists. Patients were asked to 
record three values, and the better two reproducible 
( f 20 1 min - ‘) values on each occasion were kept for 
analysis. The amplitude of changes in daily PEFR 
(dPEFR) was calculated from the following formula: 
(highest value - lowest value) x lOO/(highest value). 
Vital capacity (VC) and forced expiratory volume in one 
second (FEV,) were measured by spirometry before and 
at the end of the treatment period. In addition, metha- 
choline inhalation tests were performed with the 
Wright’s nebulizer at tidal volume breathing for 2 min 
according to a standardized procedure (4), and a pro- 
vocative concentration that caused a 20% decrease in 
FEV, (PC,,) was determined. 
Patients attended the clinic on a weekly basis. 
Asthma symptoms, possible adverse effects and 
changes in concomitant medication were evaluated 
from asthma diaries, and full blood count, serum 
biochemistry and urinalysis were performed. 
All data were expressed as mean & SE. Statistical 
analysis was performed using a paired Student’s 
t-test, and a P value of less than 0.05 was considered 
significant. 
Results 
Two patients in the menthol group were with- 
drawn because of an uncomfortable sensation in the 
upper airway, thus 21 patients completed the full 
protocol. As shown in Table 1, there were no sig- 
nificant differences in VC, FEV, dPEFR and PC,, 
between the menthol group and the placebo group. 
In the placebo group, these values were unchanged 
throughout the trial. In contrast, menthol therapy 
did not significantly alter VC or FEV,, but produced 
a decrease in dPEFR from 17.4 + 3.3 to 11.2 f 3.3% 
and an increase in PC,, from 5.1 + 1.2 to 
10.7 * 2.8 mg ml- ’ (PcO.05, n= 11 in each case). 
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Table I Clinical data before and after treatment with menthol or placebo 
Menthol group Placebo group 
Before After Difference Before After Difference 
Lung function 
VC (% predicted) 944 f 1.2 95.3 f 0.9 ns. 93.8 f 1.0 950 f 1.1 ns. 
FEV, (% predicted) 81.6*2.1 84.2 f 3.0 ns. 85.5 f 1.8 84.4 f 2.6 n.s. 
dPEFR (%) 17-4 f 3.3 11.2jZ3.3 PCO.05 16.8 f 2.7 17.0 f 3.6 n.s. 
PC,, (mg ml - ‘) 5.1 f 1.2 10.7 f 2.8 PCO.05 5.8 f 1.1 6.5 f 2.5 n.s. 
Wheezing episodes (week - ‘) 3.3 f 0.3 1.8 f 0.7 PCO.05 2.9 f 0.3 2.7 f 0.5 n.s. 
MD1 inhalation (puff week ‘) 5.2 f 0.4 2.1 f 0.3 P<O.Ol 4.8 f 0.5 4.4 f 0.3 n.s. 
VC, vital capacity; FEV,, forced expiratory volume in one second; dPEFR, diurnal variation in peak expiratory flow rate; 
PC,,, provocative concentration of methacholine required to cause a 20% fall in FEV,; MDI, metered-dose inhaler; n.s., not 
significant. Values are expressed as mean f SE; n= 11 for menthol group and n= 10 for placebo group. 
None of the patients showed apparent adverse effects 
in either group. In the menthol group, patients had 
fewer wheezing episodes and less consumption of 
bronchodilators after the treatment. 
Discussion 
Our study indicates that menthol might be ben- 
eficial in the treatment of mild asthma. As our 
preliminary experiment showed that menthol vapour 
did not produce acute bronchodilatory effects, we 
examined a long-term effect of this compound on 
airway hyperresponsiveness in asthmatic patients. 
We found that 4-week inhalation of menthol vapour 
decreased diurnal variation in PEFR, a value that 
reflects airway excitability (5), but had no significant 
effect on FEV,. Thus, menthol may lead to an 
improvement of airway hyperresponsiveness without 
altering the magnitude of airflow limitation. This 
notion is also supported by the finding that the PC,, 
values for methacholine were increased after treat- 
ment with menthol. 
Although the mechanism of efficacy of menthol on 
airway hyperresponsiveness is uncertain, menthol 
and other aromatic vapours have been used in the 
symptomatic treatment of upper respiratory infec- 
tions because of its ability to stimulate laryngeal cold 
receptors (5). Recent evidence suggests that menthol 
inhibits the cough reflex (2). In addition, menthol 
can decrease intracellular free Ca*+ concentration 
through an inhibition of voltage-dependent Ca*’ 
channels, thereby producing hyperpolarization of 
various types of cells (7,8). Therefore, these mech- 
anisms could be operating in the observed effect of 
menthol in the present study. 
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